A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI)
University of Wisconsin, Madison
Summary
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic ratio. Participants can expect to be on study for follow up up to 5 years.
Eligibility
- Age range
- 40+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: For all participants * Participants should have no contraindications to undergo MRI scan as part of radiotherapy planning and treatment. * Lumpectomy cavity must be clearly visible on CT and MRI scan at radiotherapy simulation. * Pregnancy test negative in women of child bearing potential (WOCBP). * The participant must consent to be in the study and must have signed an approved consent form conforming with institutional guidelines. * Participants with a history of non-breast malignancies are eligible if they have been disease-free for 5 or more years prior and are deemed…
Interventions
- RadiationMRIdian Radiation Treatment Unit
partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
Location
- University of Wisconsin Carbone Cancer CenterMadison, Wisconsin